U.S., March 29 -- ClinicalTrials.gov registry received information related to the study (NCT06900647) titled 'Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer' on March 16.
Brief Summary: This a phase 1 study to evaluate the safety and preliminary efficacy of cisplatin combined with bortezomib in patients with recurrent or metastatic breast cancer.
Study Start Date: Jan. 01
Study Type: INTERVENTIONAL
Condition:
Metastatic Breast Cancer
Recurrent Breast Cancer
Intervention:
DRUG: Bortezomib (B)
1.3mg/m2, IV, D1, D4, D8 and D11, every 3 weeks
DRUG: Cisplatin (CDDP)
50mg/m2, IV, D1-3, every 3 weeks
DRUG: Bortezomib (B)
1.5mg/m2, IV, D1, D4, D8 and D11, every 3 weeks
DRUG: Bortezomib (B)
1.7mg/m2, IV, D1, D4, D8 ...